All Stories

  1. IgG Glycosylation Analysis in Patients with Ring14 Syndrome Unveils Novel Pathomechanisms and New Therapy Perspectives
  2. Longitudinal Effects of Neuropsychomotor Therapy on Clinical Outcomes in Autism Spectrum Disorder: An 18-Month Multicenter Rehabilitation Study
  3. IgG Glycosylation Analysis in Patients with Ring14 Syndrome Unveils Novel Pathomechanisms and New Therapy Perspectives
  4. Exploring Copy Number Variants in a Cohort of Children Affected by ADHD: Clinical Investigation and Translational Insights
  5. Clinical and Behavioral Correlates of Blood Acylcarnitine Profiles in Children with Autism Spectrum Disorder: A Cross-Sectional Analysis
  6. Acute transient psychotic episode as presenting sign of Mucopolysaccharidosis III A (Sanfilippo Syndrome type A) in an adolescent patient
  7. POLR3A rare variants in a patient with intellectual disability, ataxic gait and cortical malformations: a case-report
  8. Glycosylation Pathways Targeted by Deregulated miRNAs in Autism Spectrum Disorder
  9. Impaired myoblast differentiation and muscle IGF‐1 receptor signaling pathway activation after N‐glycosylation inhibition
  10. Correction: The Griffiths Autism Early Screening (GAES): A Novel Developmental Test for Screening Autism Spectrum Disorder
  11. Paroxysmal Dystonic Posturing Mimicking Nocturnal Leg Cramps as a Presenting Sign in an Infant with DCC Mutation, Callosal Agenesis and Mirror Movements
  12. Instrumented assessment of gait disturbance in PMM2-CDG adults: a feasibility analysis
  13. Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2‐CDG
  14. The Griffiths Autism Early Screening (GAES): A Novel Developmental Test for Screening Autism Spectrum Disorder
  15. Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
  16. Higher frequency of TMEM199-CDG in the southern mediterranean area is associated with c.92G>C (p.Arg31Pro) mutation
  17. Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
  18. Copy Number Variations in Children with Tourette Syndrome: Systematic Investigation in a Clinical Setting
  19. PARK2 microdeletion in a multiplex family with autism spectrum disorder
  20. Early Sensory Profile in Autism Spectrum Disorders Predicts Emotional and Behavioral Issues
  21. Sensory Profiles in School-Aged Children with Autism Spectrum Disorder: A Descriptive Study Using the Sensory Processing Measure-2 (SPM-2)
  22. Defective IGF-1 prohormone N-glycosylation and reduced IGF-1 receptor signaling activation in congenital disorders of glycosylation
  23. Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study
  24. COG6‐CDG : Novel variants and novel malformation
  25. Active site variants in STT3A cause a dominant type I congenital disorder of glycosylation with neuromusculoskeletal findings
  26. Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data
  27. Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?
  28. N-Glycomics of Human Erythrocytes
  29. Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients
  30. Clinical, molecular and glycophenotype insights in SLC39A8-CDG
  31. N-Glycomics of Human Erythrocytes
  32. Psychometric Properties of the Italian Version of the Assessment of Identity Development in Adolescence (AIDA)
  33. Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder
  34. Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis
  35. Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG)
  36. A Novel Homozygous <b><i>ALG12</i></b> Mutation in a Patient with CDG Type Ig: New Report of a Case with a Mild Phenotype
  37. Incidence of Autism Spectrum Disorder in Youths Affected by Gilles de la Tourette Syndrome Based on Data from a Large Single Italian Clinical Cohort
  38. Self- and Parent-Reported Psychological Symptoms in Young Cancer Survivors and Control Peers: Results from a Clinical Center
  39. Epilepsy and movement disorders in CDG : Report on the oldest‐known MOGS‐CDG patient
  40. International consensus guidelines for phosphoglucomutase 1 deficiency ( PGM1‐CDG ): Diagnosis, follow‐up, and management
  41. HILIC-UPLC-MS for high throughput and isomeric N-glycan separation and characterization in Congenital Disorders Glycosylation and human diseases
  42. Potential Associations Among Alteration of Salivary miRNAs, Saliva Microbiome Structure, and Cognitive Impairments in Autistic Children
  43. COVID-19 Pandemic Outbreak and its Psychological Impact on Patients with Rare Lysosomal Diseases
  44. A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG)
  45. Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG
  46. Disentangling Restrictive and Repetitive Behaviors and Social Impairments in Children and Adolescents with Gilles de la Tourette Syndrome and Autism Spectrum Disorder
  47. Clinical correlates in children with autism spectrum disorder and CNVs: Systematic investigation in a clinical setting
  48. Aberrant Sialylation in a Patient with a <i>HNF1α</i> Variant and Liver Adenomatosis
  49. Metal and essential element levels in hair and association with autism severity
  50. ALG12-CDG: novel glycophenotype insights endorse the molecular defect
  51. Adjunct Diagnostic Value of Transcranial Magnetic Stimulation in Mucopolysaccharidosis-Related Cervical Myelopathy: A Pilot Study
  52. Diagnostic and Prognostic Value of Transcranial Magnetic Stimulation in Mucopolysaccharidosis-Related Cervical Myelopathy
  53. Hyperkinetic movement disorders in congenital disorders of glycosylation
  54. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up
  55. SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals
  56. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder
  57. Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
  58. Online comprehension across different semantic categories in preschool children with autism spectrum disorder
  59. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients
  60. CSF N-Glycoproteomics Using MALDI MS Techniques in Neurodegenerative Diseases
  61. International clinical guidelines for the management of phosphomannomutase 2‐congenital disorders of glycosylation: Diagnosis, treatment and follow up
  62. A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses
  63. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses
  64. Expanded Newborn Screening Using Tandem Mass Spectrometry: Seven Years of Experience in Eastern Sicily
  65. KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature
  66. Study on the Role of Polymorphisms of the SOX-6 and MYB Genes and Fetal Hemoglobin Levels in Sicilian Patients with β-Thalassemia and Sickle Cell Disease
  67. CSF N-Glycomics Using MALDI MS Techniques in Alzheimer’s Disease
  68. Errata Corrige, Thalassemia Reports 2017; 7:6392
  69. Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder
  70. An Eye Tracker based Computer System to Support Oculomotor and Attention Deficit Investigations
  71. MALDI-MS profiling of serumO-glycosylation andN-glycosylation in COG5-CDG
  72. Granulocyte–Colony Stimulating Factor plus Plerixafor in Patients with β-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ Cells with Specific Gene Expression Profile
  73. Familial 18q12.2 deletion supports the role of RNA-binding protein CELF4 in autism spectrum disorders
  74. Early-Onset Epileptic Encephalopathy in infants with different forms of Congenital Disorders of Glycosylation (CDG)
  75. Prominent neurological involvement in Dercum disease
  76. Unusual Neurological Presentation of Nevoid Basal Cell Carcinoma Syndrome (Gorlin-Goltz Syndrome)
  77. Response to Alpha-Interferon Treatment of the Congenital Dyserythropoietic Anemia type I in Two Sicilian Beta Thalassemia Carriers
  78. ALG1-CDG: Clinical and Molecular Characterization of 39 Unreported Patients
  79. New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia
  80. CSF N-glycoproteomics for early diagnosis in Alzheimer's disease
  81. Electroclinical features of a patient with GLUT1 deficiency syndrome and adult onset periodic weakness
  82. Congenital Dyserythropoietic Anemias: Molecular Diagnosis and Diagnostic Approach in a Cohort of Italian Patients
  83. Miglustat Does Not Prevent Neurological Involvement in Niemann Pick C Disease
  84. Defective CSF sialylation in autism spectrum disorders
  85. Optimizing the Molecular Diagnosis of GALNS: Novel Methods to Define and Characterize Morquio-A Syndrome-Associated Mutations
  86. Electroclinical Features of Early-Onset Epileptic Encephalopathies in Congenital Disorders of Glycosylation (CDGs)
  87. Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial
  88. Familial 1q22 microduplication associated with psychiatric disorders, intellectual disability and late-onset autoimmune inflammatory response
  89. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation
  90. Development and Recent Progresses of Gene Therapy for β-Thalassemia
  91. Congenital Disorders of Glycosylation with Emphasis on Cerebellar Involvement
  92. Report of Two Never Treated Adult Sisters with Aromatic l-Amino Acid Decarboxylase Deficiency: A Portrait of the Natural History of the Disease or an Expanding Phenotype?
  93. First US Phase I Clinical Trial Of Globin Gene Transfer For The Treatment Of Beta-Thalassemia Major
  94. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major
  95. Imaging findings of mucopolysaccharidoses: a pictorial review
  96. Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death
  97. Phenotypic spectrum and prevalence of INPP5E mutations in Joubert Syndrome and related disorders
  98. Eye-tracking evaluation of ocular motility in Pompe disease
  99. Hurler disease (MPS IH): Evidence for the need of increased awareness by caring non-metabolic physicians
  100. DPM2-CDG: A muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy
  101. Glycomics of pediatric and adulthood diseases of the central nervous system
  102. An unknown cause of aortic valve stenosis: polycythemia vera
  103. Early Miglustat Therapy in Infantile Niemann-Pick Disease Type C
  104. Phenotypic heterogeneity in hereditary motor neuropathy type V: a new case report series
  105. Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera
  106. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene
  107. Sporadic motor neuron disease in a familial novel SOD1 mutation: Incomplete penetrance or chance association?
  108. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy
  109. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation
  110. Krabbe leukodystrophy in a selected population with high rate of late onset forms: longer survival linked to c.121G>A (p.Gly41Ser) mutation
  111. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab
  112. Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study
  113. Secondary disorders of glycosylation in inborn errors of fructose metabolism
  114. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms
  115. Mucopolysaccharidosis VI: the Italian experience
  116. Mass spectrometry in the characterization of human genetic N‐glycosylation defects
  117. Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS
  118. Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia
  119. Inter- and intrafamilial variability in mucolipidosis II (I-cell disease)
  120. Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease
  121. Chitotriosidase and Alzheimers Disease
  122. Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype)
  123. Intrathecal chitotriosidase and the outcome of multiple sclerosis
  124. Substrate reduction therapy in the infantile form of Tay-Sachs disease
  125. Callosal anomalies with interhemispheric cyst: Expanding the phenotype
  126. Congenital Insensitivity to Pain with Anhidrosis (NTRK1 Mutation) and Early Onset Renal Disease: Clinical Report on Three Sibs with a 25-Year Follow-Up in One of Them
  127. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia
  128. Chitotriosidase activity in colostrum from African and Caucasian women
  129. Chitotriosidase in Patients with Acute Ischemic Stroke
  130. Human aldolase A natural mutants: relationship between flexibility of the C-terminal region and enzyme function
  131. Startle epilepsy complicating aspartylglucosaminuria
  132. A Novel Exon 1 Mutation in a Patient with Atypical Lafora Progressive Myoclonus Epilepsy Seen as Childhood‐onset Cognitive Deficit
  133. A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions
  134. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers
  135. Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation
  136. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria
  137. Plasma chitotriosidase activity in patients with ?-thalassemia
  138. Plasma Chitotriosidase Activity in Acute Plasmodium falciparum Malaria
  139. Mutation analysis of the MECP2 gene in patients with Rett syndrome
  140. White matter changes mimicking a leukodystrophy in a patient with Mucopolysaccharidosis: characterization by MRI
  141. Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease
  142. Extraneurologic symptoms as presenting signs of Sanfilippo disease
  143. Plasma chitotriosidase activity in β-thalassemia major: a comparative study between Sicilian and Sardinian patients
  144. Plasma Chitotriosidase Activity Is a Marker of Recovery in Transplanted Patients Affected by β-Thalassemia major
  145. Arthrogryposis Multiplex Congenita and Pituitary Ectopia. A Case Report
  146. β-Hexosaminidase, α-d-mannosidase, and β-mannosidase expression in serum from patients with carbohydrate-deficient glycoprotein syndrome type I
  147. Tuberous breast deformity in an adolescent girl with Hurler-Scheie syndrome
  148. Carbohydrate-deficient glycoprotein syndromes: The Italian experience
  149. Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I
  150. Extraordinary bone involvement in a Gaucher disease type I patient
  151. Clinical and Neuroradiological Follow-Up in Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
  152. Peripheral lymphocyte subsets and other immune aspects in rett syndrome
  153. Point Mutations Throughout the GLI3 Gene Cause Greig Cephalopolysyndactyly Syndrome
  154. Rett Syndrome: Photographic Evidence of Rapid Regression
  155. Developmental patterns and neuropsychological assessment in patients with carbohydrate-deficient glycoconjugate syndrome type IA (phosphomannomutase deficiency)
  156. Plasma Chitotriosidase Activity in Patients with β-Thalassemia
  157. Lysosomal enzyme activities in serum and leukocytes from patients with carbohydrate-deficient glycoprotein syndrome type IA (phosphomannomutase deficiency)
  158. Phosphomannomutase deficiency is the main cause of carbohydrate-deficient glycoprotein syndrome with type I isoelectrofocusing pattern of serum sialotransferrins
  159. Two new mild homozygous mutations in Gaucher disease patients: Clinical signs and biochemical analyses
  160. Carbohydrate deficient glycoprotein (CDG) syndrome type I.
  161. Evidence for Genetic Heterogeneity in the Carbohydrate-Deficient Glycoprotein Syndrome Type I (CDG1)
  162. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes
  163. Familial Dandy-Walker variant in CDG syndrome
  164. Haemostatic Studies in Carbohydrate-deficient Glycoprotein Syndrome Type I
  165. Olivopontocerebellar atrophy leading to recognition of carbohydrate-deficient glycoprotein syndrome type I
  166. Pancreatitis and organic acidemias
  167. Carbohydrate deficient glycoprotein syndrome type I: ophthalmic aspects in four Sicilian patients.